Cavalry Biosciences is pursuing a $75 million Series B to advance its first two drug candidates into clinical testing. CEO Preston Klassen told Endpoints the funding plan is intended to support bringing the initial pipeline programs through early-stage execution. Cavalry is described as the first biotech to emerge from Jupiter Bioventures. The focus on starting clinical development signals a transition from concept and preclinical work to human validation for its inaugural candidates. For investors and partners, the financing effort is a bellwether for how incubator-backed companies are targeting larger next rounds to secure clinical runway and reduce dilution risk as early assets near first-patient dosing.